Abnormal evoked potentials in autoimmune glial fibrillary acidic protein astrocytopathy.

Autoimmune GFAP astrocytopathy Central conduction time Somatosensory evoked potentials Transcranial magnetic stimulation Visual evoked potentials

Journal

eNeurologicalSci
ISSN: 2405-6502
Titre abrégé: eNeurologicalSci
Pays: Netherlands
ID NLM: 101667077

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 09 12 2019
revised: 04 02 2020
accepted: 08 02 2020
entrez: 25 2 2020
pubmed: 25 2 2020
medline: 25 2 2020
Statut: epublish

Résumé

Autoimmune GFAP astrocytopathy is a new clinical entity and only a limited number of cases have been reported. Here we report the results of multimodal central conduction studies performed in a case of this disorder. A 72-year-old woman developed gradual cognitive decline and gait disturbance. A neurological examination revealed moderate amnesia, papilloedema, and pyramidal tract impairment of the bilateral lower limbs. The diagnosis of autoimmune GFAP astrocytopathy was made based on the typical MRI findings of periventricular radial linear gadolinium enhancement in the brain and longitudinally extensive lesions in the spinal cord, and anti-GFAP antibody detected in the cerebrospinal fluid. Somatosensory evoked potentials and transcranial magnetic stimulation studies revealed prolongation of conduction times. Visual evoked potentials showed an unusual W-shaped pattern. To our knowledge, this is the first neurophysiological demonstration of prolonged central conduction times in the autoimmune GFAP astrocytopathy. Further investigations are needed to establish the clinical value the neurophysiological examinations in this disorder.

Identifiants

pubmed: 32090177
doi: 10.1016/j.ensci.2020.100229
pii: S2405-6502(20)30008-3
pii: 100229
pmc: PMC7026450
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100229

Informations de copyright

© 2020 The Authors.

Déclaration de conflit d'intérêts

None.

Références

Ann Neurol. 2017 Feb;81(2):298-309
pubmed: 28120349
Neuroimmunomodulation. 2018;25(1):1-6
pubmed: 29788018
JAMA Neurol. 2016 Nov 1;73(11):1297-1307
pubmed: 27618707
Clin Electroencephalogr. 1990 Jul;21(3):162-7
pubmed: 2364558
Handb Clin Neurol. 2013;116:375-86
pubmed: 24112910
Curr Opin Neurol. 2019 Jun;32(3):452-458
pubmed: 30724768
J Neuroimmunol. 2019 Sep 15;334:576999
pubmed: 31254929

Auteurs

Ryo Tokimura (R)

Department of Neurology, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima 960-1295, Japan.

Nozomu Matsuda (N)

Department of Neurology, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima 960-1295, Japan.

Shunsuke Kobayashi (S)

Department of Neurology, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima 960-1295, Japan.

Akio Kimura (A)

Department of Neurology and Geriatrics, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan.

Kazuaki Kanai (K)

Department of Neurology, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima 960-1295, Japan.

Classifications MeSH